Organovo Holdings, Inc. (NASDAQ:ONVO – Get Free Report) was the target of a large decline in short interest during the month of July. As of July 15th, there was short interest totalling 80,000 shares, a decline of 18.7% from the June 30th total of 98,400 shares. Based on an average daily volume of 170,300 shares, the short-interest ratio is presently 0.5 days.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on Organovo in a research note on Saturday, July 13th. They set a “sell” rating on the stock.
Check Out Our Latest Report on Organovo
Organovo Trading Up 2.7 %
Organovo (NASDAQ:ONVO – Get Free Report) last released its quarterly earnings data on Friday, May 31st. The medical research company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.13. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.08 million. On average, equities research analysts forecast that Organovo will post -1.4 EPS for the current fiscal year.
Organovo Company Profile
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Further Reading
- Five stocks we like better than Organovo
- Overbought Stocks Explained: Should You Trade Them?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- What is the FTSE 100 index?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Investors Need to Know to Beat the Market
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.